In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 409-412

  Pannacciulli, Ivo ^a   Ballarino, Paola ^b   Castello, Giorgio ^b   Arboscello, Eleonora ^b   Botta, Marco ^b   Tredici, Simona ^b   Lerza, Roberto ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Granulocyte macrophage colony forming units; Hematotoxicity; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; NAVELBINE; PACLITAXEL;

ADHERENT CELL; ARTICLE; BONE MARROW CULTURE; CELL SUSPENSION; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; ETOPOSIDE; HEMATOPOIETIC STEM CELLS; HUMANS; PACLITAXEL; VINBLASTINE;

EID: 0032898578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sledge GW, Robert N, Sparano JA, Cobeligh M, Goldstein LJ, Neuberg D, et al: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 5 (suppl. 8) 15-18, 1994.
2. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clinical Oncology 14: 2713-2721, 1996.
3. Holmes FA: Combination chemotherapy with taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 5: 17-21, 1994.
4. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995.
5. Rowinsky EK, Donehower RC: Antimicrotubule agents. In: De Vita VT jr, Hellman S, Rosenberg SA. Cancer, Principles and practice of oncology. 5th ed. Philadelphia, Lippincott, Raven Pub.: 467-483, 1997.
6. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, et al: Phase I and pharmacologic study of paclitaxel and DDP with granulocyte colony- stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020, 1993.
7. Rowinsky EK, Citardi M, Noe DA, Donehower RC: Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 737-740, 1993.
8. Parker RJ, Dabholkar MD, Lee K-B, Bostoick-Burton F, Reed E: Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monogr Natl Cancer Inst 15: 83-88, 1993.
9. Liebmann JE, Fisher J, Teage D, Cook JA: Sequence dependence of paclitaxel (TAXOL) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25-31, 1994.
10. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Sem Oncol 23: 37-43, 1996.
11. Kennedy MJ, Zahurak ML, Donehower RC, et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony- stimulating factor in women with previously-treated metastatic breast cancer. J Clin Oncol 14: 783-786, 1996.
12. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
13. Akutsu M, Kano Y, Tsunoda S, Suzuki K, Yazawa Y, Miura Y.: Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro. Eur J Cancer 31: 2341-2346, 1995.
14. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y: In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37: 525-530, 1996.
15. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, et al: Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31: 92-97, 1995.
16. Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schroder J, Wilke H, et al: Activity-and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in DDP-sensitive and -refractory human ovarian carcinoma cell lines, Br J Cancer 74: 224-228, 1996.
17. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Cancer 69: 299-306, 1994.
18. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, et al: Taxol in combination with doxorubicin or etoposide. Cancer 72: 2705-2711, 1993.
19. Fennelly DM, Rigas JR, Chou D, Miller VA, Pisters KMW, Grant SC, et al: Phase I trial of edatrexate plus paclitaxel using an administration schedule with demonstrated in vitro synergy. Proc ASCO 365 (abs), 1994.
20. Adams DJ: Synergy of Navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 35: 327 (abs), 1994.
21. Perez EA, Hack F, Fletcher T: Sequence-dependent cytotoxicity of taxol and epotoside in lung and breast human cancer cell lines. Proc Am Soc Clin Oncol 14: 491 (abs), 1995.
22. Cook JA, Fisher J, Teague D, et al: Sequence dependence of paclitaxel combined with cisplatin or alkylators in human cancer cells. Proc Am Assoc Cancer Res 35: 1975A (abs), 1994.
23. Zoli W, Flamigni A, Frassineti GL, et al: In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Treat 34: 63-69, 1995.
24. Ali FMK: Separation of human blood and bone marrow cells. Wright Ed., Bristol, 1986.
25. Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44: 227-230, 1966.
26. Castello G. Mela GS, Cerruti A, Mencoboni M, Lerza R: Azidothymidine and Interferon- α in vitro effects on hematopoiesis: protective in vitro activity of IL-1 and GM-CSF. Experimental Hematology 23: 1367-1371, 1995.
27. Fleiss JK: Statistical methods for rates and proportions, 2nd edition, New York, Wiley, 1974.
28. Holmes FA: Combination chemotherapy with taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 5: 17-21, 1994.
29. Holmes FA: Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Sem Oncol 22: 9-15, 1995.
30. Woud WR, Schmid SM, Plowman J: In vitro and in vivo combination chemotherapy evaluation of taxol with doxorubicin and topotecan. Second National Cancer Institute Workshop on Taxol and Taxus, G10 (abs), 1992.
31. Hortobagyi GN, Ibrahim N: Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Sem Oncol 23: 53-57, 1996.